Cargando…

Future Directions in Maintenance Therapy in Multiple Myeloma

Autologous stem cell transplantation (ASCT) has been a backbone of therapy for newly diagnosed patients with multiple myeloma eligible for high-dose therapy for decades. Survival outcomes have continued to improve over time, in part because of the incorporation of highly effective induction regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Holstein, Sarah A., Suman, Vera J., Hillengass, Jens, McCarthy, Philip L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197068/
https://www.ncbi.nlm.nih.gov/pubmed/34073689
http://dx.doi.org/10.3390/jcm10112261
_version_ 1783706833663295488
author Holstein, Sarah A.
Suman, Vera J.
Hillengass, Jens
McCarthy, Philip L.
author_facet Holstein, Sarah A.
Suman, Vera J.
Hillengass, Jens
McCarthy, Philip L.
author_sort Holstein, Sarah A.
collection PubMed
description Autologous stem cell transplantation (ASCT) has been a backbone of therapy for newly diagnosed patients with multiple myeloma eligible for high-dose therapy for decades. Survival outcomes have continued to improve over time, in part because of the incorporation of highly effective induction regimens prior to ASCT as well as post-ASCT maintenance therapy. Randomized phase III clinical trials have helped establish lenalidomide maintenance as a standard of care. However, as nearly all patients will eventually experience disease relapse, there continues to be significant interest in developing novel maintenance strategies to improve upon lenalidomide maintenance. In this review, we summarize the available evidence for the use of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies as post-ASCT maintenance therapies as well as discuss future directions and unanswered questions in the field.
format Online
Article
Text
id pubmed-8197068
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81970682021-06-13 Future Directions in Maintenance Therapy in Multiple Myeloma Holstein, Sarah A. Suman, Vera J. Hillengass, Jens McCarthy, Philip L. J Clin Med Review Autologous stem cell transplantation (ASCT) has been a backbone of therapy for newly diagnosed patients with multiple myeloma eligible for high-dose therapy for decades. Survival outcomes have continued to improve over time, in part because of the incorporation of highly effective induction regimens prior to ASCT as well as post-ASCT maintenance therapy. Randomized phase III clinical trials have helped establish lenalidomide maintenance as a standard of care. However, as nearly all patients will eventually experience disease relapse, there continues to be significant interest in developing novel maintenance strategies to improve upon lenalidomide maintenance. In this review, we summarize the available evidence for the use of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies as post-ASCT maintenance therapies as well as discuss future directions and unanswered questions in the field. MDPI 2021-05-24 /pmc/articles/PMC8197068/ /pubmed/34073689 http://dx.doi.org/10.3390/jcm10112261 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Holstein, Sarah A.
Suman, Vera J.
Hillengass, Jens
McCarthy, Philip L.
Future Directions in Maintenance Therapy in Multiple Myeloma
title Future Directions in Maintenance Therapy in Multiple Myeloma
title_full Future Directions in Maintenance Therapy in Multiple Myeloma
title_fullStr Future Directions in Maintenance Therapy in Multiple Myeloma
title_full_unstemmed Future Directions in Maintenance Therapy in Multiple Myeloma
title_short Future Directions in Maintenance Therapy in Multiple Myeloma
title_sort future directions in maintenance therapy in multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197068/
https://www.ncbi.nlm.nih.gov/pubmed/34073689
http://dx.doi.org/10.3390/jcm10112261
work_keys_str_mv AT holsteinsaraha futuredirectionsinmaintenancetherapyinmultiplemyeloma
AT sumanveraj futuredirectionsinmaintenancetherapyinmultiplemyeloma
AT hillengassjens futuredirectionsinmaintenancetherapyinmultiplemyeloma
AT mccarthyphilipl futuredirectionsinmaintenancetherapyinmultiplemyeloma